161 related articles for article (PubMed ID: 35830929)
21. Early cytomegalovirus reactivation leaves a specific and dynamic imprint on the reconstituting T cell compartment long-term after hematopoietic stem cell transplantation.
Lugthart G; van Ostaijen-Ten Dam MM; Jol-van der Zijde CM; van Holten TC; Kester MG; Heemskerk MH; Bredius RG; van Tol MJ; Lankester AC
Biol Blood Marrow Transplant; 2014 May; 20(5):655-61. PubMed ID: 24462981
[TBL] [Abstract][Full Text] [Related]
22. Possible Impact of Cytomegalovirus-Specific CD8
Ogonek J; Varanasi P; Luther S; Schweier P; Kühnau W; Göhring G; Dammann E; Stadler M; Ganser A; Borchers S; Koehl U; Weissinger EM; Hambach L
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1046-1053. PubMed ID: 28344058
[TBL] [Abstract][Full Text] [Related]
23. Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation.
Lin TS; Zahrieh D; Weller E; Alyea EP; Antin JH; Soiffer RJ
Transplantation; 2002 Jul; 74(1):49-54. PubMed ID: 12134098
[TBL] [Abstract][Full Text] [Related]
24. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
25. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis.
Ljungman P; Brand R; Einsele H; Frassoni F; Niederwieser D; Cordonnier C
Blood; 2003 Dec; 102(13):4255-60. PubMed ID: 12933590
[TBL] [Abstract][Full Text] [Related]
26. Immunologic Monitoring after Allogeneic Stem Cell Transplantation: T-SPOT.CMV and QuantiFERON-CMV, Are They the Same?
Callens R; Colman S; Delie A; Schauwvlieghe A; Lodewyck T; Selleslag D; Reynders M; Kerre T; Padalko E
Transplant Cell Ther; 2023 Jun; 29(6):392.e1-392.e7. PubMed ID: 36963722
[TBL] [Abstract][Full Text] [Related]
27. Impact of Anti-CMV IgG Titers and CD34 Count Prior to Hematopoietic Stem Cell Transplantation from Alternative Donors on CMV reactivation.
Arcuri LJ; Schirmer M; Colares M; Maradei S; Tavares R; Moreira MCR; Araujo RC; Lerner D; Pacheco AGF
Biol Blood Marrow Transplant; 2020 Nov; 26(11):e275-e279. PubMed ID: 32750422
[TBL] [Abstract][Full Text] [Related]
28. [The effect of donor cytomegalovirus serological status on the outcome of allogeneic stem cell transplantation].
Liu J; Fu Q; Wang Y; Wang FR; Han W; Ma YR; Yan CH; Han TT; Wang JZ; Wang ZD; Zhang XH; Xu LP; Liu KY; Huang XJ; Sun YQ
Zhonghua Nei Ke Za Zhi; 2021 May; 60(5):459-465. PubMed ID: 33906276
[No Abstract] [Full Text] [Related]
29. Specific donor HLA allotypes as predictors of cytomegalovirus disease risk in acute myeloid leukemia.
Min GJ; Kim HJ; Kim TG; Hyun YS; Hyun SJ; Baek IC; Yoon SY; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW
HLA; 2020 Oct; 96(4):445-455. PubMed ID: 32506817
[TBL] [Abstract][Full Text] [Related]
30. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.
Neuenhahn M; Albrecht J; Odendahl M; Schlott F; Dössinger G; Schiemann M; Lakshmipathi S; Martin K; Bunjes D; Harsdorf S; Weissinger EM; Menzel H; Verbeek M; Uharek L; Kröger N; Wagner E; Kobbe G; Schroeder T; Schmitt M; Held G; Herr W; Germeroth L; Bonig H; Tonn T; Einsele H; Busch DH; Grigoleit GU
Leukemia; 2017 Oct; 31(10):2161-2171. PubMed ID: 28090089
[TBL] [Abstract][Full Text] [Related]
31. Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality.
Liu LW; Yn A; Gao F; Olson M; Crain M; Abboud R; Westervelt P; Abboud C; Vij R; Stockerl-Goldstein K; Pusic I; Cashen AF; Schroeder MA
Transplant Cell Ther; 2022 Aug; 28(8):510.e1-510.e9. PubMed ID: 35598841
[TBL] [Abstract][Full Text] [Related]
32. Donor serostatus has an impact on cytomegalovirus-specific immunity, cytomegaloviral disease incidence, and survival in seropositive hematopoietic cell transplant recipients.
Ugarte-Torres A; Hoegh-Petersen M; Liu Y; Zhou F; Williamson TS; Quinlan D; Sy S; Roa L; Khan F; Fonseca K; Russell JA; Storek J
Biol Blood Marrow Transplant; 2011 Apr; 17(4):574-85. PubMed ID: 20688181
[TBL] [Abstract][Full Text] [Related]
33. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
Almyroudis NG; Jakubowski A; Jaffe D; Sepkowitz K; Pamer E; O'Reilly RJ; Papanicolaou GA
Transpl Infect Dis; 2007 Dec; 9(4):286-94. PubMed ID: 17511819
[TBL] [Abstract][Full Text] [Related]
34. Application of CMV-IVIg as prophylaxis against cytomegalovirus reactivation in allogeneic hematopoietic stem cell transplantation patients.
Cui J; Zhou Y; Zhao K; Li X; Zhang H; Zhang X; Sun Y; Long B
Clin Transplant; 2024 Apr; 38(4):e15300. PubMed ID: 38555576
[TBL] [Abstract][Full Text] [Related]
35. Cellular Immunity to Predict the Risk of Cytomegalovirus Infection in Kidney Transplantation: A Prospective, Interventional, Multicenter Clinical Trial.
Jarque M; Crespo E; Melilli E; Gutiérrez A; Moreso F; Guirado L; Revuelta I; Montero N; Torras J; Riera L; Meneghini M; Taco O; Manonelles A; Paul J; Seron D; Facundo C; Cruzado JM; Gil Vernet S; Grinyó JM; Bestard O
Clin Infect Dis; 2020 Dec; 71(9):2375-2385. PubMed ID: 32076718
[TBL] [Abstract][Full Text] [Related]
36. CMV-Specific Immune Response-New Patients, New Insight: Central Role of Specific IgG during Infancy and Long-Lasting Immune Deficiency after Allogenic Stem Cell Transplantation.
Zdziarski P
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30641912
[TBL] [Abstract][Full Text] [Related]
37. Relationship of reconstituted adaptive and innate cytomegalovirus (CMV)-specific immune responses with CMV viremia in hematopoietic stem cell transplant recipients.
Barron MA; Gao D; Springer KL; Patterson JA; Brunvand MW; McSweeney PA; Zeng C; Barón AE; Weinberg A
Clin Infect Dis; 2009 Dec; 49(12):1777-83. PubMed ID: 19911937
[TBL] [Abstract][Full Text] [Related]
38. Reconstitution of cytomegalovirus-specific T-cell immunity following unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide.
Huntley D; Giménez E; Pascual MJ; Remigia MJ; Amat P; Vázquez L; Hernández M; Hernández-Boluda JC; Gago B; Piñana JL; García M; Martínez A; Mateo E; Gozalbo-Rovira R; Albert E; Solano C; Navarro D
Bone Marrow Transplant; 2020 Jul; 55(7):1347-1356. PubMed ID: 32205853
[TBL] [Abstract][Full Text] [Related]
39. QuantiFERON-CMV and monitor predict cytomegalovirus, mortality, and graft-versus-host disease in transplant recipients.
Souan L; Jazar HA; Nashwan S; Sughayer MA
J Med Virol; 2023 Nov; 95(11):e29250. PubMed ID: 38009250
[TBL] [Abstract][Full Text] [Related]
40. Protective immunity transferred by infusion of cytomegalovirus-specific CD8(+) T cells within donor grafts: its associations with cytomegalovirus reactivation following unmanipulated allogeneic hematopoietic stem cell transplantation.
Luo XH; Huang XJ; Liu KY; Xu LP; Liu DH
Biol Blood Marrow Transplant; 2010 Jul; 16(7):994-1004. PubMed ID: 20167279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
